gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

NudC domain containing 1

Top mentioned proteins: V1a, vascular endothelial growth factor, mdm2, Phosphogluconate Dehydrogenase, CML28
Papers on CML66
OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.
Ge et al., Shanghai, China. In Carcinogenesis, 2014
Ovarian cancer-associated antigen 66 (OVA66), also known as CML66 (GenBank Accession No. AF283301), was first identified in an ovarian carcinoma complementary DNA (cDNA) expression library and was shown to play a role in tumorigenesis.
Structural features and chaperone activity of the NudC protein family.
Derewenda et al., Charlottesville, United States. In J Mol Biol, 2011
The fourth distantly related member of the family, CML66, contains a NudC-like domain.
Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.
Wu et al., Boston, United States. In Clin Cancer Res, 2010
EXPERIMENTAL DESIGN: We examined responses developing against CML66, an immunogenic antigen preferentially expressed in myeloid progenitor cells identified from a patient with chronic myelogenous leukemia who attained long-lived remission following CD4+ donor lymphocyte infusion (DLI).
RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells.
Ge et al., Shanghai, China. In Cancer Lett, 2008
CML66 may play an oncogenic role in ways of favoring tumor cells proliferation, invasion and metastasis-associated with multiple pathways.
Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity.
Ge et al., Shanghai, China. In Cancer Sci, 2008
study identified a novel gene, OVA66, which was expressed significantly higher in cancer patients than normal controls; IgG level against OVA66 was significantly elevated in the serum of cancer patients from different histological types of cancer [OVA66]
Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes.
Yasukawa et al., Japan. In Cancer Sci, 2008
CML66 is a newly identified differentiation antigen that is expressed broadly in human leukemia and solid tumors, but its physiological function remains unknown.
Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.
Ritz et al., Boston, United States. In Clin Cancer Res, 2005
We previously reported the identification of a high titer-specific immunoglobulin G response against two novel leukemia-associated antigens, CML28 and CML66, which correlated with immune-induced remission.
A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.
Yang et al., Houston, United States. In J Immunol, 2004
An alternative promoter (CML66-S short isoform) has been identified in combination with alternative splicing as a novel mechanism for regulation of the epitope generation of a self-tumor antigen.
[Cloning, prokaryotic expression of CML66 and preparation of its polyclonal antibody].
Ge et al., Shanghai, China. In Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2003
AIM: To clone and express CML66 cDNA and to prepare rabbit anti-CML66 antibody.
Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia.
Scheinberg et al., New York City, United States. In Semin Hematol, 2003
Antigens under investigation include bcr-abl, PR1, Wilms tumor protein (WT1), minor histocompatibility antigens (mH), CML-66, CML-28, and survivin.
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.
Ritz et al., Boston, United States. In Proc Natl Acad Sci U S A, 2001
This report describes a tumor-associated antigen, termed CML66, initially cloned from a chronic myelogenous leukemia (CML) cDNA expression library.
share on facebooktweetadd +1mail to friends